2026-04-20T01:52:39Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/87972024-03-14T11:52:07Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Aldred, Jason 3efc0f48-3958-4907-ae8f-c3b0f11b415f 600 Anca-Herschkovitsch, Marieta e1a4479e-6471-49b3-92d2-17279109f9d7 600 Antonini, Angelo 9ce63bac-d8d3-4150-b0b5-8b0e73e5eb90 600 Bajenaru, Ovidiu 81e64575-348b-4cac-8eba-01f69d10997c 600 Bourgeois, Paul b487d6bc-0f84-4b8f-818a-2240c88e3a5f 600 Cubo Delgado, Esther 131 600 0000-0003-0018-1182 Davis, Thomas L. e3f0ce6d-083c-4b71-a06a-59a170e7e077 600 Iansek, Robert c3e67ffe-d7fd-4cc4-8e0b-713fd18e398a 600 Kovács, Norbert 149d8665-cabe-4e26-8309-242f580acc9c 600 Kukreja, Pavnit 310f6280-4048-40e8-a3ad-51110ca1805b 600 Onuk, Koray cfe5ead9-ed59-40b4-83ae-e3a663c50006 600 Pontieri, Francesco E. 0e19bd2c-02a2-4948-84bf-c05c0f7c94c8 600 Robieson, Weining 8b327a37-7971-4e04-910d-ffb34f40484e 600 Siddiqui, Mustafa S. 1ac8fffa-db1e-4ee2-8a6d-0461cd702bcc 600 Simu, Mihaela c804cd12-7b9d-499a-823a-f929b9eb69f2 600 Standaert, David G. 6da922f3-858b-4e9f-9899-3e00594a5650 600 Chaudhuri, K. Ray 9c6dffc7-c13f-407e-b690-89052e59d909 600 2024-03-11T11:15:23Z 2024-03-11T11:15:23Z 2020-09 1758-2024 http://hdl.handle.net/10259/8797 10.2217/nmt-2020-0021 1758-2032 Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment. application/pdf eng Future Medicine Neurodegenerative Disease Management. 2020, V. 10, n. 5, p. 309-323 https://doi.org/10.2217/nmt-2020-0021 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess 5-2-1 Criteria for advanced PD Dyskinesia LCIG Levodopa Levodopa-carbidopa intestinal gel Off time Parkinson’s disease Sistema nervioso-Enfermedades Medicina Neurología Nervous system-Diseases Medicine Neurology Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Neurodegenerative Disease Management 10 5 309 323 THUMBNAIL Aldred-ndm_2020.pdf.jpg Aldred-ndm_2020.pdf.jpg IM Thumbnail image/jpeg 4105 https://riubu.ubu.es/bitstream/10259/8797/4/Aldred-ndm_2020.pdf.jpg 0f1acc2483154f7bd21aef9d90d513d6 MD5 4 LICENSE license.txt license.txt text/plain; charset=utf-8 999 https://riubu.ubu.es/bitstream/10259/8797/3/license.txt b295bcbce42e2caabeb0c623d3860c06 MD5 3 CC-LICENSE license_rdf license_rdf application/rdf+xml; charset=utf-8 805 https://riubu.ubu.es/bitstream/10259/8797/2/license_rdf 4460e5956bc1d1639be9ae6146a50347 MD5 2 ORIGINAL Aldred-ndm_2020.pdf Aldred-ndm_2020.pdf application/pdf 1784383 https://riubu.ubu.es/bitstream/10259/8797/1/Aldred-ndm_2020.pdf 75c7d576889268942a7d2ff0cf45e423 MD5 1 10259/8797 oai:riubu.ubu.es:10259/8797 2024-03-14 12:52:07.648 Repositorio Institucional de la Universidad de Burgos bubrep@ubu.es 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